Datasets: selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
Amanda J. Watson(University of Manchester), Donald Ogilvie(Bioscience Research), H. Nikki March(University of Manchester), Gemma V. Hopkins(University of Manchester), Alex Stowell(University of Manchester), Samantha Hitchin(University of Manchester), Sarah V. Holt(Pharma Nord (United Kingdom)), Helen Small(University of Manchester), Allan M. Jordan(Signature Research (United States)), Ian D. Waddell(Charles River Laboratories (United Kingdom)), Habiba Begum(University of Manchester), Stuart Jones(University of Manchester), Bohdan Waszkowycz(University of Manchester), Rebecca Newton(University of Manchester)
Cited by 0
Related Papers
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
|Cancer Research|2005|710
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
|British Journal of Cancer|2012|111
Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint
|Journal of Cell Science|2005|108